Group 1 - The brain engineering concept experienced significant market activity, with several companies in the sector seeing notable stock price increases [1] - Innovation Medical (002173) reached the daily limit increase, indicating strong investor interest [1] - Xiangyu Medical saw a rise of over 15%, reflecting positive market sentiment towards the brain engineering sector [1] Group 2 - Other companies such as Aipeng Medical (300753), Sanbo Brain Science (301293), and Entropy Technology (301330) also experienced slight increases in their stock prices, contributing to the overall positive trend in the industry [1]

Group 1 - The core viewpoint of the article is that Aipeng Medical (300753) has announced its R&D investment for 2024, which amounts to 33.28 million yuan, representing 8.24% of its operating revenue [1] - A new entity, Shenzhen Pengrui Brain Science, was established in August 2024 and is currently in the initial investment phase [1]

Core Viewpoint - The company disclosed its research and development (R&D) investment for 2024, indicating a focus on innovation despite being in the early stages of a new subsidiary [1] Summary by Categories R&D Investment - The total R&D investment for 2024 is reported to be 33.28 million yuan, which represents 8.24% of the company's operating revenue [1] Company Development - Shenzhen Pengrui Brain Science Technology Co., Ltd. was established in August 2024 and is currently in the initial investment phase [1]

一、募集资金基本情况 经中国证券监督管理委员会证监许可〔2018〕1802号文核准，并经深圳证券交易所同 意，本公司由主承销商广发证券股份有限公司采用网下向投资者询价配售和网上按市值向 持有深圳市场非限售A股或非限售存托凭证市值的社会公众投资者定价发行相结合的方式， 向社会公众公开发行人民币普通股（A股）股票2,020万股，发行价为每股人民币15.80元， 共计募集资金319,160,000.00元，坐扣承销和保荐费用35,000,000.00元后的募集资金为 284,160,000.00元，已由主承销商广发证券股份有限公司于2018年12月10日汇入本公司募集 资金监管账户。另减除上网发行费、招股说明书印刷费、申报会计师费、律师费、评估费 等与发行权益性证券直接相关的新增外部费用21,229,976.33元后，公司本次募集资金净额 为262,930,023.67元。上述募集资金到位情况业经天健会计师事务所（特殊普通合伙）验证， 并由其出具《验资报告》（天健验〔2018〕450号）。 二、募集资金存放和管理情况 为规范公司募集资金管理，保护投资者权益，根据中国证监会《上市公司募集资金监 管规则》《深圳证券交易 ...

（原标题：突然大爆发，601606股价创新高！这一领域迎利好，主力资金抢筹股出炉） 我国脑机接口正处于由基础研究向临床应用转化的重要阶段。 7月31日，市场全天震荡调整，三大股指午后均跌超1%。算力概念股活跃，英维克、川润股份等多股涨 停。创新药概念延续强势，钢铁、煤炭等周期股集体调整，油气、有色金属等板块跌幅居前。 军工股尾盘爆发，长城军工(601606)涨停再创新高，北方长龙涨17.22%，捷强装备、内蒙一机等个股尾 盘快速上涨。 国家医保局支持脑机接口等新技术进入临床并收费 据央视新闻报道，为支持药品和医疗器械创新发展，国家医保局制定新上市药品首发价格机制，新增了 100多项与医疗新技术相关的价格项目。国家医保局从立项、定价等方面入手，畅通新技术的收费通 道，助力满足临床急需的新技术新产品加快收益回报。 | | | 主力资金净流入额居前的脑机接口概念股一览 | | | | --- | --- | --- | --- | --- | | 代码 | 简称 | 总市值 (亿元) | 年内涨跌幅 (%) | 7月31日丰力 净流入额 | | 300418 | 昆仑万维 | 450.67 | -6.70 | (亿 ...

Group 1 - The stock price of Aipeng Medical reached 31.39 yuan, an increase of 2.13 yuan or 7.28% from the previous trading day [1] - The opening price was 29.95 yuan, with a highest point of 31.98 yuan and a lowest point of 29.41 yuan, resulting in a trading volume of 196,100 hands and a transaction amount of 600 million yuan [1] - Aipeng Medical operates in the medical device sector, focusing on pain management, nasal care, and minimally invasive medical products [1] Group 2 - On July 31, the National Healthcare Security Administration announced support for brain-computer interface technologies to enter clinical use and be charged, adding new fee items such as "brain-computer interface implantation fee" and "brain-computer interface adaptation fee" [1] - This policy directly benefits medical companies involved in brain-computer interface technology [1]

来源：金融界 金融界消息 截至2025年7月31日收盘，爱朋医疗（300753）报收于31.39元，上涨7.28%，换手率 23.79%，成交量19.61万手，成交金额6.00亿元。 资金流向方面，今日主力资金净流入3162.54万元，占比成交额5.27%。其中，超大单净流入2286.91万 元、占成交额3.81%，大单净流入875.62万元、占成交额1.46%，中单净流出流出998.81万元、占成交额 1.67%，小单净流出2163.72万元、占成交额3.61%。 爱朋医疗最新一期业绩显示，截至2025一季报，公司营业总收入6482.19万元、同比减少26.13%，归属 净利润1764.92万元，同比减少1400.65%，扣非净利润1794.98万元，同比减少1143.48%，流动比率 3.490、速动比率2.959、资产负债率18.53%。 天眼查商业履历信息显示，江苏爱朋医疗科技股份有限公司，成立于2001年，位于南通市，是一家以从 事医药制造业为主的企业。企业注册资本12604.8万人民币，实缴资本6060万人民币。公司法定代表人 为王凝宇。 通过天眼查大数据分析，江苏爱朋医疗科技股份有限公司共对外投 ...

| 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300003 | 乐普医疗 | 6230.96万 | 5.49% | -1220.74万 | -1.08% | -5010.22万 | -4.42% | | 688656 | 浩欧博 | 3805.71万 | 13.20% | -1941.68万 | -6.74% | -1864.03万 | -6.47% | | 300238 | 冠昊生物 | 3491.91万 | 8.34% | 1570.15万 | 3.75% | -5062.06万 | -12.09% | | 300753 爱朋医疗 | | 3162.54万 | 5.27% | -998.81万 | -1.67% | -2163.72万 | -3.61% | | 300289 | 利德曼 | 3117.42万 | 27.46% | -1921.39万 | -16.93% | -1196.03万 | -10.54 ...

7月31日，人脑工程概念上涨0.27%，今日主力资金流入7729.22万元，概念股14只上涨，19只下跌。 主力资金净流入居前的分别为科大讯飞（2.28亿元）、创新医疗（9399.58万元）、乐普医疗（6230.96 万元）、熵基科技（6031.32万元）、爱朋医疗（3162.54万元）。 来源：金融界 序号代码名称最新价涨跌幅主力净流入主力净占比1002230科大讯飞48.780.762.28亿元8.28%2002173创 新医疗15.347.729399.58万元8.27%3300003乐普医疗15.560.846230.96万元5.49%4301330熵基科技 29.213.86031.32万元12.2%5300753爱朋医疗31.397.283162.54万元5.27%6002195岩山科技5.741.232957.49 万元1.87%7301293三博脑科50.083.582790.86万元3.88%8603610麒盛科技12.662.592028.90万元 9.16%9300678中科信息33.980.651515.56万元3.66%10688273麦澜德33.76-0.591193.99万元9. ...

消息面上，为支持药品和医疗器械创新发展，国家医保局制定新上市药品首发价格机制，新增了100多 项与医疗新技术相关的价格项目。神经系统类立项指南统一设立"脑机接口置入费""脑机接口适配费"等 价格项目，脑机接口技术成熟获批进入临床后，可快速进入临床应用并收费。耳鼻喉类立项指南统一设 立"人工耳蜗植入费""发音装置安装费"等价格项目，鼓励医疗机构帮助更多患者"听得见、说得出"。放 射治疗类立项指南统一设立"质子放疗""重离子放疗"等价格项目，促进高端医疗设备的临床转化应用。 与此同时，为鼓励药品研发创新，国家医保局还制定了新上市药品首发价格机制。 格隆汇7月31日｜脑机接口概念股拉升，其中，创新医疗逼近涨停，爱朋医疗、三博脑科、熵基科技、 麒盛科技、岩山科技等跟涨。 ...